VJHemOnc is committed to improving our service to you

SOHO 2020 | LB-100 in low and intermediate risk MDS

VJHemOnc is committed to improving our service to you

Rami Komrokji

Rami Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, explores the rationale and trial design of a Phase I study evaluating LB-100, a phosphatase inhibitor, in low and intermediate-risk myelodysplastic syndrome (MDS) patients with or without deletion 5q, a common genetic abnormality in MDS. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter